New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
Sun Pharma announced new two-year open-label extension data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The safety profile remained consistent with prior clinical experience through two years, with no deaths, thrombosis or major adverse cardiovascular events at the FDA-approved 8 mg twice-daily dose. Durability was strong: 93.9% of baseline responders maintained response at Week 108, and 96.8% of Week 52 responders held response through Week 108.
Key figures
- Drug Name
- LEQSELVI (deuruxolitinib)
- Phase Of Trial
- open-label extension study (post-approval, up to 2 years)
- Approved dose
- 8 mg twice-daily
- Eadv presentations sun pharma
- 7
- Total sun pharma congress presentations
- 22
- Week 108 maintained response baseline responders
- 93.9%
- Week 52 responders maintaining response at week 108
- 96.8%
- Baseline nonresponders achieving response by week 52
- 76.6%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.